摘要
目的探讨利用基因芯片技术检测乙型肝炎病毒(HBV)前C区/BCP区以及P区基因变异的临床意义。方法应用基因芯片技术检测220例不同临床类型乙肝患者的血清前C区n t1896、1814,HBVC区基因启动子(BCP)n t1762和1764以及P区n t552、528位点的变异。结果220份血清中未检出1例n t1814突变,n t1896变异率为19.09%(42/220)。其中HB eA g阳性n t1896的变异率为21.4%(9/42),HB eA g阴性n t1896的变异率为78.6%(33/42),后者变异率显著高于前者。BCP双变异的检出率为69.09%(152/220),轻度、中度、重度慢性乙型肝炎、肝硬化以及肝癌患者中BCP双变异的检出率分别为21.88%(7/32),66.67%(56/84),100%(28/28),100%(76/76)。BCP双变异阳性与阴性组相比,ALT、A ST、HBVDNA无明显差异,TB il、ALB、CHE相差有显著性。P区YM DD基序n t552、528位点变异率为5.45%(12/220)。结论利用基因芯片对同一份标本可同时检测多位点的变异,快速方便,具有一定的临床应用价值。
Objective To investigate the clinical value of gene chip technique in the detection of HBV per-core/basic core promoter and P region variance. Methods Detection of gene mutations in HBV pre-core nt1896,1814,basic core promoter （BCP）nt1762,1764 and P region nt552. 528 in 220 patients with hepatitis B of various clinical types. Results No mutation occurred at nt1814 in 220 patients. The rate of mutation on nt1896 was 19.09% （42/220）. The rate of pre-core nt1896 was 21.4% （9/42） in the patients with HBeAg positive and 78.6% （33/42） in the patients with HBeAg negative ,there was significant difference between the later and the former. The rates for BCP nt1762 and 1764 in light ,moderate ,severe chronic hepatitis,liver cirrhosis and hepatoma was 21.88%（7/32）, 66. 670% （56/84）, 100% （28/28）, 100% （76/76） respectively. Compared with BCP double mutation group and non-mutation group,ALT, AST,HBVDNA had no obvious difference; TBil ,ALB,CHE difference had significance. The mutation rates of motif YMDD（nt522,528）in HBV P region was 5.45% （12/22）. Conclusion Utilize genetic chip to measure many different variant sites at the same time with one sample. It is convenient and fast. Gene chip has clinical value in the investigation of hepatic disease.
出处
《现代检验医学杂志》
CAS
2005年第5期14-15,共2页
Journal of Modern Laboratory Medicine
